Lasting ustekinumab benefits seen in psoriatic arthritis

The final results of a 2-year, phase III study assessing the clinical efficacy and safety of ustekinumab in 615 patients with active psoriatic arthritis confirm that joint- and skin-related improvements are maintained. Data from the randomized, double blind, placebo-controlled PSUMMIT 1 study...googletag.display('div-gpt-ad-cta');
Source: Skin and Allergy News - Category: Dermatology Tags: CME-candidate RHEUM News RHEUM Psoriatic arthritis RHEUM Spondyloarthropathies SAN Clinical News SAN News SAN Psoriasis Source Type: news